Form 4: RVMD officer trades under 10b5-1; 50,425 shares held

Rhea-AI Filing Summary

Revolution Medicines (RVMD) reported insider activity by General Counsel Jeff Cislini. On October 17, 2025, he exercised 12,000 stock options at $36.57 and sold 12,000 shares at $55 pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.

After these transactions, he beneficially owned 50,425 shares, including 43,910 restricted stock units. The exercised option carried a $36.57 exercise price, became exercisable on June 15, 2024, and expires on June 16, 2030. Following the activity, 18,000 derivative securities remained beneficially owned.

Insider Trade Summary

Net Seller: 12,000 shares ($660,000)

Net Sell 3 txns

Insider Cislini Jeff

Role General Counsel

Sold 12,000 shs ($660K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	12,000	$0.00	--
Exercise	Common Stock	12,000	$36.57	$439K
Sale	Common Stock	12,000	$55.00	$660K

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 shares (Direct); Common Stock — 62,425 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. Includes 43,910 restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/17/2025		M(1)		12,000	A	$36.57	62,425(2)	D
Common Stock	10/17/2025		S(1)		12,000	D	$55	50,425(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$36.57	10/17/2025		M(1)			12,000	06/15/2024	06/16/2030	Common Stock	12,000	$0	18,000	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.

2. Includes 43,910 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RVMD disclose on Form 4?

Jeff Cislini, General Counsel, exercised 12,000 options at $36.57 and sold 12,000 shares at $55 on October 17, 2025.

Was the RVMD insider trade under a Rule 10b5-1 plan?

Yes. The filing notes the trade was made under a Rule 10b5-1 plan adopted on March 13, 2025.

How many RVMD shares does the insider hold after the transactions?

He beneficially owned 50,425 shares after the transactions, including 43,910 RSUs.

What were the prices involved in the RVMD insider transactions?

Option exercise price was $36.57; sale price was $55 per share.

What are the key dates for the exercised RVMD stock options?

The options were exercisable on June 15, 2024 and expire on June 16, 2030.

How many derivative securities remain after the RVMD insider trade?

The filing shows 18,000 derivative securities beneficially owned after the transactions.

What is the insider’s role at RVMD?

He is an Officer, serving as General Counsel.